Y0000401
Pimobendan for system suitability
European Pharmacopoeia (EP) Reference Standard
别名:
Pimobendan, 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C19H18N4O2
CAS号:
分子量:
334.37
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
![4-Chloro-N-[2-(4-hydroxyphenyl)ethyl]benzamide AldrichCPR](/deepweb/assets/sigmaaldrich/product/structures/139/662/1ce3ff3b-f928-4434-88d9-f4981db0fc47/640/1ce3ff3b-f928-4434-88d9-f4981db0fc47.png)
等級
pharmaceutical primary standard
API 家族
pimobendan
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CC(C(C1=CC=C(NC(C2=CC=C(OC)C=C2)=N3)C3=C1)=NN4)CC4=O
InChI
1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
InChI 密鑰
GLBJJMFZWDBELO-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Pimobendan for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 3 Oral
儲存類別代碼
6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
[Calcium mobilizers and calcium sensitizers].
Masashi Arai
Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 9, 417-422 (2012-06-26)
M W S Martin et al.
The Journal of small animal practice, 51(8), 428-436 (2010-07-31)
To review the association between clinical signs and diagnostic findings and the survival time of dogs with dilated cardiomyopathy (DCM), and any influence of treatment prescribed. A retrospective observational study of 367 dogs with DCM. Survival times until death or
Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
Adrian Boswood et al.
The Veterinary record, 168(8), 222-222 (2011-04-16)
Domenico Caivano et al.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 14(3), 431-444 (2012-08-14)
Interventional cardiac procedures are traditionally performed using fluoroscopy, or, more recently, transesophageal echocardiography (TEE). Neither modality is widely available to practicing cardiologists worldwide. We examined whether balloon valvuloplasty of pulmonic stenosis (PS) and transarterial occlusion of patent ductus arteriosus (PDA)
Andrea C Lantis et al.
American journal of veterinary research, 72(12), 1646-1651 (2011-12-01)
To evaluate the effect of administration of the labeled dosage of pimobendan to dogs with furosemide-induced activation of the renin-angiotensin-aldosterone system (RAAS). 12 healthy hound-type dogs. Dogs were allocated into 2 groups (6 dogs/group). One group received furosemide (2 mg/kg
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门